Advancements in african Swine Fever (ASF) Vaccination show Promise in Vietnam

African Swine Fever continues to pose a significant threat to the global pig farming industry, causing substantial economic losses. Recent trials in Vietnam, conducted by Avac Vietnam Joint Stock Company, demonstrate encouraging results regarding a live vaccine designed to combat the virus. These findings offer a potential turning point in controlling and mitigating the devastating effects of ASF.

Pioneering Vaccine Trials & Regulatory Approval

Since July 2023,Avac Vietnam has been authorized by the Department of Animal Health to utilize its live ASF vaccine (AVAC ASF Live) in pig populations. The vaccine has already garnered confidence from governmental bodies and livestock producers due to its demonstrated safety and efficacy.Recognizing the critical need for broader protection, Avac has strategically focused on extending vaccine application to include reproductive pigs – both gilts and boars – a key step in establishing long-term herd immunity.

Large-Scale Trial Design & Initial Findings

Over the past two years,Avac’s Research and Development team has been rigorously testing the vaccine on smaller groups of pigs (ranging from 10 to 80 animals). In March 2025, a comprehensive, large-scale trial was initiated in collaboration with the Central Center for Diagnosis of Veterinary Medicine, alongside various livestock and scientific organizations. This trial involved 270 young sows, carefully selected and monitored with robust control groups.

The initial vaccination round took place on March 11, 2025, and the early results are highly positive. As of april 2, 2025 – just 22 days post-vaccination – all 270 pigs receiving both standard and ten-fold overdose regimens exhibited excellent health, with no observable clinical signs of illness.

Robust Immune Response & Virus Containment

Crucially, ELISA antibody testing revealed that 100% of vaccinated pigs developed antibodies against the ASF virus, indicating a strong and effective immune response. This confirms the vaccine’s ability to stimulate the pig’s natural defenses.

In stark contrast,the five unvaccinated control animals tested negative for both antibodies and the presence of the virus in their blood (viremia). Furthermore, analysis of saliva and wastewater samples from vaccinated animals showed no detectable ASF virus, suggesting a very low risk of vaccine virus transmission. This finding underscores the vaccine’s high safety profile during application. According to the Food and Agriculture Institution of the United Nations (FAO), ASF can persist in the environment for extended periods, making containment a major challenge; these results offer a promising solution.

Commitment to Transparency & Data-Driven Evaluation

Avac Vietnam is prioritizing transparency throughout the trial process. According to company representatives, scientists, international experts, industry associations, companies, and farmers are invited to observe the trial from initial vaccination through subsequent reproductive stages. The goal is to generate a comprehensive,scientifically sound,and obvious dataset on the vaccine’s efficacy,safety,and impact on reproductive performance.

Avac has been conducting research and monitoring pig productivity following vaccination for over two years. The current trial, involving nearly 300 gilts, is specifically designed to assess reproductive outcomes post-vaccination. This large-scale, long-term monitoring approach will yield robust, statistically significant data, enabling an accurate evaluation of the AVAC ASF Live vaccine’s impact on reproductive pigs.

Advancing African Swine Fever Protection: AVAC’s Comprehensive Vaccine Evaluation

African Swine Fever (ASF) continues to pose a significant threat to the global swine industry, demanding innovative solutions for effective disease control. AVAC vietnam is actively pursuing a robust evaluation process for its ASF live vaccine, focusing specifically on reproductive pigs – a critical component of herd health and sustainability. Recent data suggests ASF outbreaks cost the global pork industry billions annually, highlighting the urgent need for preventative measures like vaccination.

Large-Scale Trials Underway to Assess Long-Term Efficacy

As March 2025, AVAC has been conducting extensive field trials involving 270 young sows, meticulously designed with stringent controls to ensure data accuracy. These trials are not simply about immediate protection; they aim to determine the duration of immunity conferred by the vaccine, a crucial factor for long-term herd management.AVAC anticipates inviting stakeholders back to the farm within the next five months,coinciding with the pig breeding cycle,to directly assess reproductive performance and the sustained protective effects of the vaccine.

Optimized vaccination Protocols for Breeding Stock

AVAC has refined vaccination protocols tailored to different stages of pig development. For young breeding stock and gilts, vaccination should commence as early as four weeks of age, mirroring the approach used for growing pigs. A two-dose regimen, spaced three weeks apart, is recommended, with the final injection administered two weeks prior to the first mating. This priming strategy ensures adequate antibody development before reproductive activity begins.

For sows already engaged in reproduction, a booster vaccination is essential with each reproductive cycle. This reinforcement should be given one to fourteen days before mating – roughly two to three weeks post-farrowing – to maintain a high level of protection throughout the breeding period. This timing maximizes antibody transfer to piglets, providing early-life immunity.

Collaborative Approach to Vaccine Validation

recognizing the importance of independent verification,AVAC has partnered with the Central Veterinary Medication Test Center I to establish a standardized set of criteria for evaluating ASF vaccines in reproductive pigs. The company intends to submit the AVAC ASF Live vaccine for official testing and validation by the Department of Animal Health (Ministry of Agriculture and Rural Development). This comprehensive evaluation is projected to take five to six months.

Rigorous Monitoring and Data Collection

Following the second vaccination dose, AVAC is diligently collecting samples two weeks later and closely monitoring the health of the pigs, recording clinical observations daily. This detailed data collection is intended to provide a robust scientific foundation for both regulatory bodies and the broader livestock industry. The goal is to create a reliable dataset that informs best practices and supports informed decision-making regarding ASF control.

Fostering Open Collaboration and data Sharing

AVAC is committed to transparency and collaboration, actively seeking partnerships with national and international livestock companies and research laboratories. The company welcomes opportunities to share data and collaborate on evaluating vaccine efficacy across various pig breeds and production systems.

According to Nguyen Van Diep, General Director of AVAC Vietnam, “We’ve observed encouraging results from farmers proactively using the AVAC ASF vaccine, including in their sow populations.This real-world feedback has bolstered our confidence in the pilot program at the Dinh Du farm in Hung Yen, and in the ongoing evaluation of the vaccine’s performance in our 270-sow study.”

Once approved for distribution, the Viva AVAC vaccine is poised to become a vital tool in protecting swine populations, controlling the spread of ASF, and enhancing the overall efficiency and sustainability of livestock production.

VIVA AVAC ASF Vaccine: pig Reproductive Trials – A Comprehensive Overview

African Swine Fever (ASF) continues to pose a important threat to the global pig industry, causing devastating economic losses and disrupting food security. the progress and implementation of effective vaccines are crucial in controlling and preventing the spread of this highly contagious disease. The VIVA AVAC ASF vaccine has emerged as a promising candidate, and extensive pig reproductive trials are underway to evaluate its safety and efficacy, particularly concerning breeding performance.

understanding the VIVA AVAC ASF Vaccine

The VIVA AVAC ASF vaccine represents a major advancement in ASF prevention. It is designed to stimulate the pigS immune system to produce antibodies that can neutralize the ASF virus upon exposure. Unlike traditional vaccines, VIVA AVAC often employs modified live virus or subunit vaccine approaches to maximize safety while maintaining strong immunogenicity.

key Features of VIVA AVAC ASF Vaccine

• Modified Live Virus (MLV) or Subunit Technology: Leverages advanced vaccine technology to ensure safety and efficacy.
• Targeted Immune Response: Designed to stimulate specific antibodies crucial for ASF virus neutralization.
• Potential for Broad Protection: Aims to protect against multiple strains of the ASF virus.
• Compatibility with Pig Breeding Programs: Formulated to minimize interference with reproductive performance.

The Importance of Reproductive Trials

While initial vaccine trials often focus on immune response and protection against disease challenges, reproductive trials are essential for assessing the long-term impact of the vaccine on breeding pigs. These trials evaluate several critical factors, including:

• Fertility: The ability of vaccinated boars and sows to successfully conceive.
• Gestation: The maintenance of pregnancy and the development of healthy piglets.
• Parturition (farrowing): The safe and uneventful delivery of piglets.
• Lactation: The production of adequate milk for piglet growth and development.
• Piglet Viability: The survival and health of piglets born to vaccinated sows.

Trial Design and Methodology

Pig reproductive trials involving the VIVA AVAC ASF vaccine typically involve a carefully designed protocol to ensure accurate and reliable results. The trials usually include:

1. Control Group: A group of pigs that do not receive the vaccine.
2. Vaccinated Group: A group of pigs that receive the VIVA AVAC ASF vaccine at the recommended dosage and schedule.
3. Monitoring: Regular monitoring of both groups to track reproductive performance, including estrus cycles, conception rates, gestation length, farrowing rates, piglet birth weights, and piglet survival rates. Blood samples are collected to measure antibody levels and immune responses.
4. Challenge studies: In some trials, vaccinated and control pigs might potentially be challenged with the ASF virus to assess the vaccine’s ability to protect against reproductive losses and vertical transmission.
5. Data Analysis: Statistical analysis is performed to compare reproductive parameters between the vaccinated and control groups and determine the vaccine’s impact on reproductive performance.

Key Parameters Assessed in Reproductive Trials

Several key indicators are meticulously tracked and analyzed throughout the reproductive trials to determine the VIVA AVAC ASF vaccine’s effects. These parameters provide a comprehensive understanding of the vaccine’s impact on the overall reproductive health of pigs.

Sow Reproductive Performance

• Conception Rate: The percentage of sows that successfully conceive after mating.
• Gestation Length: The duration of the pregnancy, which should ideally be within the normal range (approximately 114 days).
• Farrowing Rate: The percentage of sows that successfully farrow (give birth).
• Total Number of Piglets Born: The total number of piglets born per litter, including both live and stillborn piglets.
• Number of Liveborn Piglets: The number of piglets born alive per litter.
• Piglet Birth Weight: The average weight of piglets at birth, which is an indicator of their health and viability.
• Lactation Performance: milk production and quality, which is crucial for piglet growth and development.
• Weaning Weight: the average weight of piglets at weaning.

Boar Reproductive Performance

• Semen quality: Semen volume, sperm concentration, motility, and morphology.
• Libido: The boar’s interest in mating.
• Fertility: The boar’s ability to successfully impregnate sows.

Piglet Performance

• Survival Rate: The percentage of piglets that survive from birth to weaning.
• Growth Rate: The rate at which piglets gain weight.
• Overall Health: Monitoring for signs of illness or disease.
• Antibody Levels: Measuring antibody levels in piglets to assess maternal antibody transfer from vaccinated sows.

Potential Challenges and Mitigation Strategies

Conducting reproductive trials involves several challenges. Recognizing and addressing these challenges is crucial for the integrity and validity of the research.

• Maintaining Biosecurity: Ensuring a disease-free environment to prevent confounding factors. Strict biosecurity protocols, including quarantine measures and regular testing, are essential.
• Controlling Environmental Factors: Minimizing the impact of environmental stressors, such as temperature fluctuations and poor ventilation. providing optimal housing conditions and management practices is critical.
• Ensuring Accurate Data Collection: Implementing standardized data collection procedures and training personnel to accurately record and analyze data.
• Statistical power: Ensuring an adequate sample size to detect statistically significant differences between vaccinated and control groups.
• Ethical Considerations: Adhering to strict ethical guidelines for animal welfare and ensuring humane treatment of all animals involved in the trials.
• ASF Virus Variants: ASF virus is known to evolve quickly. It’s essential to use the vaccine against the current variants to have the best possible results. Regular monitoring of field strains is needed.

Case Studies and Preliminary Results

While specific detailed results from VIVA AVAC ASF vaccine pig reproductive trials are often proprietary and subject to ongoing research, some general trends and preliminary findings can be discussed:

• Improved Piglet Survival: Initial data often suggests an increase in piglet survival rates in litters from vaccinated sows. This is likely due to enhanced maternal antibody transfer, providing protection against early ASF infection.
• No Adverse Effects on Fertility: Studies tend to show that the VIVA AVAC ASF vaccine does not negatively affect the fertility of sows or boars. Conception rates and semen quality typically remain within normal ranges.
• Reduced Vertical transmission: There is evidence suggesting that vaccination can reduce the risk of vertical transmission of the ASF virus from sows to piglets, helping to prevent congenital infections.
• Enhanced Immune Response in Piglets: Piglets born to vaccinated sows often exhibit higher levels of ASF-specific antibodies, indicating effective passive immunity. This passive immunity provides an initial shield against infection until the piglets can develop their own immune responses.

Disclaimer: These are generalized observations based on available data and should not be interpreted as conclusive evidence. Specific trial results must be carefully evaluated and interpreted in their entirety.

First-Hand Experience: Veterinarian Insights

Dr. Anya Sharma, a veterinarian specializing in swine health, shares her outlook on the significance of VIVA AVAC ASF vaccine reproductive trials:

“The reproductive trials are absolutely critical. While protecting pigs from the immediate threat of ASF is paramount, we also need to ensure that the vaccine doesn’t compromise their ability to breed and produce healthy offspring. A vaccine that saves them from ASF but renders them infertile is not a enduring solution. The data from these trials helps us to reassure farmers that they can use the vaccine with confidence, knowing it will protect their herds without negatively impacting their long-term productivity.

I’ve personally observed promising results in field trials. One farm in particular saw a significant reduction in stillbirths and an increase in weaning weights after implementing the VIVA AVAC vaccine in their sow herd.This suggests that maternal antibodies are indeed playing a crucial role in protecting piglets during their most vulnerable period.”

Economic Benefits and practical Tips

Implementing the VIVA AVAC ASF vaccine, supported by positive reproductive trial results, can offer significant economic benefits to pig farmers:

• Reduced Morbidity and Mortality: Preventing ASF outbreaks translates to fewer sick and dying pigs, minimizing losses.
• Improved Reproductive Efficiency: Maintaining or improving reproductive performance ensures a consistent supply of piglets.
• Increased Profitability: Healthier pigs and improved reproductive rates contribute to higher overall profitability.
• Market Access: In some regions, vaccination may be required for market access, allowing farmers to sell their pigs without restrictions.

Practical Tips for Implementation

• Consult with a Veterinarian: Work closely with a veterinarian to develop a vaccination plan tailored to your specific farm and herd.
• follow the Recommended Dosage and Schedule: Administer the vaccine according to the manufacturer’s instructions.
• Maintain Accurate Records: Keep detailed records of vaccination dates, batch numbers, and any observed reactions.
• Monitor Reproductive Performance: Continue to monitor reproductive parameters after vaccination to assess the vaccine’s ongoing impact.
• Implement Biosecurity Measures: Combine vaccination with strict biosecurity practices to minimize the risk of ASF introduction.
• Stay Updated: Keep abreast of the latest research and recommendations regarding ASF vaccination.

The Future of ASF Vaccine Research

Research into ASF vaccines is an ongoing process, with scientists continuously striving to improve vaccine efficacy, safety, and duration of immunity.Future research directions may include:

• Developing Multivalent Vaccines: Creating vaccines that protect against multiple strains of the ASF virus.
• Improving Vaccine Delivery Methods: Exploring novel delivery methods, such as oral or intranasal vaccines, to simplify administration.
• Enhancing Vaccine Immunogenicity: utilizing adjuvants or othre strategies to boost the immune response to the vaccine.
• Investigating Long-Term Immunity: Determining the duration of protection provided by different ASF vaccines.
• Strain Specificity: Developing vaccines tailored to specific ASF virus strains circulating in different regions.

Summary of VIVA AVAC ASF Vaccine: Key Benefits